Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial

Yang, Wenying; Liu, Jie; Shan, Zhongyan; Tian, Haoming; Zhou, Zhiguang; Ji, Qiuhe; Weng, Jianping; Jia, Weiping; Lu, Juming; Liu, Jing; Xu, Yuan; Yang, Zhaojun; Chen, Wei

doi:10.1016/s2213-8587(13)70021-4

Cited by 148 publications

(195 citation statements)

References 31 publications

Supporting

Mentioning

182

Contrasting

Order By: Relevance

“…17 Another study performed in Chinese patients showed that metformin lead to approximately 1.88 kg and 1.89 kg of weight loss after 24-week and 48-week treatment, respectively. 18 Although metformin could induce a moderate weight loss, as our and most other studies have demonstrated, the International Diabetes Federation, American Diabetes Association and European Association for the Study of Diabetes recommend metformin as the first-line treatment in all newly-diagnosed patients, regardless of weight. [12][13][14][15][16][17]19 However, few studies have assessed metformin in Asian countries, including China.…”

Section: Discussionmentioning

confidence: 83%

See 1 more Smart Citation

The Magnitude of Weight Loss Induced by Metformin is Independently Associated with BMI at Baseline in Newly Diagnosed Type 2 Diabetes: Post-hoc Analysis from Data of a Phase IV Open-labeled Trial

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 83%

“…18 In addition, weight loss did not correlate with the accumulated administration dosages of metformin. Therefore, it is possible that metformin can be developed as an anti-obesity agent independent of its hypoglycemic effect.…”

Section: Discussionmentioning

confidence: 95%

The Magnitude of Weight Loss Induced by Metformin is Independently Associated with BMI at Baseline in Newly Diagnosed Type 2 Diabetes: Post-hoc Analysis from Data of a Phase IV Open-labeled Trial

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The incidences of hypoglycaemia and other adverse events (e.g., urinary tract infection, genital infection, gastrointestinal adverse effect) induced by both drugs and the rates of therapy discontinuation of both drugs were synthesized from the meta-analysis of the included placebo-controlled RCTs. Because incidences of hypoglycaemia were not reported in the included RCTs on acarbose, we used the rates reported by an open-label, noninferiority randomised trial of acarbose in Chinese patients newly diagnosed with T2DM as a reference [47] ( Table 3).…”

Section: Clinical Effect and Adverse Effectmentioning

confidence: 99%

“…Acarbose is a classical alpha-glucosidase inhibitor used by many Chinese patients with T2DM (35.9%) [45], which is reported to have similar glucose lowering effects to metformin but with higher treatment costs [46][47][48]. It is recommended as an alternative medication for first-line therapy in China [1].…”

Section: Introductionmentioning

confidence: 99%

Cost-Effectiveness of Dapagliflozin Versus Acarbose as A Monotherapy in Type 2 Diabetes in China

2016

Value in Health

View full text Add to dashboard Cite

ObjectiveTo estimate the long-term cost-effectiveness of dapagliflozin versus acarbose as monotherapy in treatment-naïve patients with type 2 diabetes mellitus (T2DM) in China. MethodsThe Cardiff Diabetes Model, an economic model designed to evaluate the cost-effectiveness of comparator therapies in diabetes was used to simulate disease progression and estimate the long-term effect of treatments on patients. Systematic literature reviews, hospital surveys, meta-analysis and indirect treatment comparison were conducted to obtain model-required patient profiles, clinical data and costs. Health insurance costs (2015¥) were estimated over 40 years from a healthcare payer perspective. Univariate and probabilistic sensitivity analyses were performed. ResultsThe model predicted that dapagliflozin had lower incidences of cardiovascular events, hypoglycemia and mortality events, was associated with a mean incremental benefit of 0.25 quality-adjusted life-years (QALYs) and with a lower cost of ¥8,439 compared with acarbose. This resulted in a cost saving of ¥33,786 per QALY gained with dapagliflozin. Sensitivity analyses determined that the results are robust. ConclusionDapagliflozin is dominant compared with acarbose as monotherapy for Chinese T2DM patients, with a little QALY gain and lower costs. Dapagliflozin offers a well-tolerated and cost-effective alternative medication for treatment-naive patients in China, and may have a direct impact in reducing the disease burden of T2DM.

show abstract

“…Alpha-glucosidase inhibitors (AGIs) are commonly used oral hypoglycemic drugs, especially in the patient population from East Asia [9,10,11]. The guideline of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommended the use of AGIs as a potentially first-line agent or in combination with other antihyperglycemic drugs [12].…”

Section: Introductionmentioning

confidence: 99%

Molecular Docking Analysis of Novel Alpha-Glucosidase enzyme Inhibitors from Siddha Formulation Pungampoo Chooranam using Computer aided drug discovery

Nisha¹

2017

Int. J. Curr. Res. Chem. Pharm. Sci

View full text Add to dashboard Cite

Type II diabetes mellitus (T2DM) is a chronic metabolic disorder in which prevalence has been increasing steadily all over the world. As a result of this trend, it is fast becoming an epidemic in some countries of the world with the number of people affected expected to double in the next decade due to increase in ageing population, thereby adding to the already existing burden for healthcare providers, especially in poorly developed countries. Due to increased adverse event caused by conventional anti-diabetic agents researchers are at constant need of exploring alternate therapeutic strategy for clinical management of diabetes mellitus. Siddha system of traditional medicine through its valuable phytocomponents therapy provides highly beneficial effects in treating metabolic disorders such as diabetes since several centuries. Alpha-glucosidase inhibitors (AGIs) are drugs that inhibit the absorption of carbohydrates from the gut and may be used in the treatment of patients with type II diabetes or impaired glucose tolerance. There are some increasing evidence that AGIs are beneficial to prevent or delay mortality in type II diabetes. The main aim of the resent investigation is to screen the seven bioactive phytocomponents such as Beta Sitosterol, Glabrin, Kanjone, Pongol, Sterolin, Pinnantin, Quercetin, Isolonchocarpin present in the formulation Pungampoo Chooranam (PPC) against target protein Alpha-Glucosidase enzyme with PDB code 4J5Talong with the standard acarbose using computational docking analysis. The results of the present investigation clearly shows that out of eight compounds screened the compound such as Beta sitosterol, Glabrin, Sterolin and Isolonchocarpin has tendency to binding with the most significant active site 428 PHE of the enzyme target responsible for biological activity, when compare to the standard Acarbose with the binding affinity towards 392 ASP, 709 TYR and 771 GLU. Hence from the results of the present investigation it was concluded that the bioactive phytocomponents present in the formulation Pungampoo Chooranam (PPC) has significant Alpha-glucosidase inhibition activity and there by promising anti-diabetic activity and may also be effective in clinical management of type II diabetes mellitus.

show abstract

Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial

Cited by 148 publications

References 31 publications

The Magnitude of Weight Loss Induced by Metformin is Independently Associated with BMI at Baseline in Newly Diagnosed Type 2 Diabetes: Post-hoc Analysis from Data of a Phase IV Open-labeled Trial

The Magnitude of Weight Loss Induced by Metformin is Independently Associated with BMI at Baseline in Newly Diagnosed Type 2 Diabetes: Post-hoc Analysis from Data of a Phase IV Open-labeled Trial

Cost-Effectiveness of Dapagliflozin Versus Acarbose as A Monotherapy in Type 2 Diabetes in China

Molecular Docking Analysis of Novel Alpha-Glucosidase enzyme Inhibitors from Siddha Formulation Pungampoo Chooranam using Computer aided drug discovery

Contact Info

Product

Resources

About